本文選題：鼻咽癌 + 共刺激分子��； 參考：《中國(guó)腫瘤生物治療雜志》2017年07期

【摘要】：目的:檢測(cè)鼻咽癌患者外周血中T細(xì)胞表面程序性死亡分子1(programmed death-1,PD-1)、刺激分子4-1BB的表達(dá)水平,探討其在鼻咽癌中的臨床意義。方法:選取2016年10至11月福建省腫瘤醫(yī)院病理確診的鼻咽癌患者30例作為研究對(duì)象,并選取同期本院體檢中心性別、年齡相近的健康體檢者30例作為對(duì)照組。通過流式細(xì)胞術(shù)檢測(cè)外周血T細(xì)胞表面PD-1、4-1BB的表達(dá)情況以及T淋巴細(xì)胞亞群的比例。核磁共振掃描測(cè)量原發(fā)腫瘤體積。結(jié)果:鼻咽癌Ⅲ期患者外周血CD8+T細(xì)胞比例明顯低于Ⅳ期患者[(13.1±6.2)%vs(18.7±5.5)%,P0.05]。與對(duì)照組相比,CD4+T細(xì)胞上PD-1陽性表達(dá)率顯著上調(diào)[(8.7±6.5)%vs(3.87±3.0)%,P0.05]。鼻咽癌患者外周血T細(xì)胞PD-1、4-1BB分子表達(dá)水平與臨床分期、腫瘤負(fù)荷、性別及年齡無顯著相關(guān)(P0.05)。結(jié)論:鼻咽癌患者外周血PD-1和4-1BB兩種共刺激分子在患者體內(nèi)腫瘤免疫逃逸中可能存在協(xié)同效應(yīng)。聯(lián)合干預(yù)這兩種共刺激分子的信號(hào)通路可能具有更高效持久的抗腫瘤效應(yīng),可為鼻咽癌免疫治療提供新的思路。
[Abstract]:Objective: to detect the expression of 1(programmed death-1 PD-1 and stimulator 4-1BB in peripheral blood of patients with nasopharyngeal carcinoma (NPC), and to explore its clinical significance. Methods: thirty patients with nasopharyngeal carcinoma (NPC) confirmed by pathology in Fujian Cancer Hospital from October to November 2016 were selected as the study object, and 30 healthy persons with similar age and sex were selected as the control group. The expression of PD-1 4-1BB on peripheral T cells and the proportion of T lymphocyte subsets were detected by flow cytometry. The volume of primary tumor was measured by MRI. Results: the percentage of CD8 T cells in patients with NPC stage 鈪，

本文編號(hào)：1929793